3,4-bis(allyloxy)-9H-xanthen-9-one 、 二苯醚 在
二氯甲烷 作用下,
反应 11.0h,
以to yield 28.0 mg (12%) of the title compound as a white solid的产率得到1-allyl-1,3,3a,4,5,12a-hexahydro-7,13-dioxo-1,5-methano-furo[3,4-d]xanthene
参考文献:
名称:
Methods of treating diseases responsive to induction of Apoptosis and screening assays
Synthesis and evaluation of caged Garcinia xanthones
作者:Ayse Batova、Thanh Lam、Veit Wascholowski、Alice L. Yu、Athanassios Giannis、Emmanuel A. Theodorakis
DOI:10.1039/b612903j
日期:——
of the caged Garcinia xanthones, we developed a synthesis of simplified analogues that maintain the overall caged motif. The caged structure of these compounds was constructed via a site-selective Claisen/Diels-Alder reaction cascade. We found that the fully substituted caged structure, in which are included the C18 and C23 geminal methyl groups, is necessary to maintain bioactivity. Analogue had comparable
SMALL MOLECULE THERAPEUTICS, SYNTHESIS OF ANALOGUES AND DERIVATIVES AND METHODS OF USE
申请人:Theodorakis Emmanuel
公开号:US20100137421A1
公开(公告)日:2010-06-03
Provided herein are compounds that are inducers of apoptosis activators of caspases and pharmaceutically acceptable derivatives thereof. Also provided are methods of synthesis of the compounds and methods for treatment of diseases in which there is uncontrolled cell growth and spread of abnormal cells, such as cancers, by administering the compounds.
Methods of treating diseases responsive to induction of apoptosis and screening assays
申请人:Cytovia, Inc.
公开号:US07592143B2
公开(公告)日:2009-09-22
The present invention relates to screening methods useful for drug discovery of apoptosis inducing compounds. In particular, the screening methodology relates to using Apoptosis Inducing Proteins (AIPs) as a target for the discovery of apoptosis activators useful as anticancer agents. The screening methods of the present invention can employ homogenous or heterogeneous binding assays using purified or partially purified AIPs; or whole cell assays using cells with altered levels of one or more AIPs. The invention also contemplates use of gambogic acid or GA-related compounds which bind AIPs and can accordingly be used to raise antibodies useful for drug discovery. Alternatively, labeled GA is used for competitive binding assays for drug discovery. Such assays afford high throughput screening of chemical libraries for apoptosis activators.
Synthesis of caged 2,3,3a,7a-tetrahydro-3,6-methanobenzofuran-7(6H)-ones: Evaluating the minimum structure for apoptosis induction by gambogic acid
作者:Jared Kuemmerle、Songchun Jiang、Ben Tseng、Shailaja Kasibhatla、John Drewe、Sui Xiong Cai
DOI:10.1016/j.bmc.2008.02.084
日期:2008.4
We have reported the discovery of gambogic acid (GA) as a potent apoptosis inducer and the identification of transferrin receptor as its molecular target. In order to understand the basic pharmacophore of GA for inducing apoptosis and to discover novel and simplified derivatives as potential anti-cancer agents, we explored the synthesis of caged 2,3,3a, 7a-tetrahydro-3,6-methanobenzofuran-7(6H)-ones (4-oxatricyclo[4.3.1.0] decan-2-ones). Three types of 2,3,3a, 7a-tetrahydro-3,6-methanobenzofuran7(6H)-ones based on xanthone, 2-phenylchromene-4-one and benzophenone, were synthesized using a Claisen/Diels-Alder reaction cascade. All the reactions produced the targeted caged compound as well as its neo-isomer. The caged compounds based on xanthone and 2-phenylchromene-4-one were found to maintain the apoptosis inducing and cell growth inhibiting activity of GA, although with less potency. The caged compounds based on benzophenone were found to be inactive. Our study determined the minimum structure of GA for its apoptosis inducing activity, which could lead to the development of simple derivatives as potential anti-cancer drugs. (C) 2008 Elsevier Ltd. All rights reserved.
METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS